All In Biotech

Drug Trial Radar · NCT07104110

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 2025

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

  • QLH12016Drug

    oral AR PROTAC

  • abiraterone acetateDrug

    oral CYP17 inhibitor

  • enzalutamideDrug

    oral androgen receptor inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with adverse events/serious adverse events (Phase Ib)Time frame: Throughout phase Ib (approximately 1 year)
  2. The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol (Phase Ib)Time frame: From first dose of study treatment until the end of Cycle 1.
  3. Recommended phase II dose (RP2D) (Phase Ib)Time frame: Throughout phase Ib (approximately 1 year)
  4. Objective Response Rate (ORR) (Phase II)Time frame: From time of Informed Consent to confirmed progressive disease (approximately 1 year)
  5. Objective Response Rate (ORR) (Phase II)Time frame: From time of Informed Consent to confirmed progressive disease (approximately 1 year).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.